<DOC>
	<DOCNO>NCT03058458</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics different single repeat dos PIN201104 healthy volunteer patient asthma .</brief_summary>
	<brief_title>A First Time Human Study PIN201104 Healthy Volunteers Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Healthy male female subject nonchildbearing potential age 18 65 year age , good health determine medical history , physical examination , vital sign , electrocardiogram , laboratory test . Written informed consent must obtain assessment perform . Able communicate well Investigator/designee . Any known reaction study drug component concurrent recent infection clinically significant condition may place subject risk interference absorption , distribution excretion drug No QTcF interval ≥450 milliseconds , QRS complex ≥120 millisecond , Screening Positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCVAb ) human immunodeficiency virus ( HIV ) 1 and/or 2 antibody Screening . Excessive use caffeinecontaining beverage Urinary cotinine level indicative smoking history regular use tobacco nicotine containing product within 6 month screen . History regular alcohol consumption within 6 month screen 10 . Positive screen drugsofabuse cotinine . Blood donation excess 500mL within 3 month . Participation another study experimental drug within 3 month first IMP administration . Exposure 4 new chemical entity within 12 month first IMP administration . Ongoing rhinitis require treatment . Use live vaccine 28 day dose study drug telephone followup use kill vaccine 14 day dose study drug telephone followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>